The GU Oncology Now team is onsite at the 2025 American Society of Clinical Oncology Annual Meeting, providing real-time coverage of the most relevant and practice-changing research updates related to prostate, kidney, bladder, and testicular cancer.
Advertisement
Latest News
Dr. Chahoud talks about the results of the expansion cohort of the phase 1b STELLAR-002 study.
Dr. Ozay discusses her study that compared the efficacy of cabazitaxel with lutetium Lu-177 in patients with mCRPC.
The approval of darolutamide by the FDA expands treatment options available for patients diagnosed with mCSPC.
Dr. Haas provides an update on a 5-year follow-up of KEYNOTE-564 and the survival benefits of adjuvant pembrolizumab for RCC.
BCG plus mitomycin may be an alternative treatment for patients with high-risk NMBIC as access to BCG is limited worldwide.
The panel concludes with thoughts on the evolving role of lutetium-177 in metastatic castration-resistant prostate cancer.
The panel explores ARANOTE, ARASENS, and PEACE-1, emphasizing drug tolerability, toxicity trade-offs, and more.
The panel breaks down the growing role of MDT and the evolving use of radiation in oligometastatic disease.
The panel considers the ARANOTE trial of darolutamide, emphasizing its tolerability and broad eligibility criteria.
The panel examines the nuances of selecting triplet vs doublet therapy for patients with high-volume or high-risk disease.
The panel discusses how PSMA PET imaging is changing disease classification and decision-making.
The panel begins with how to explain the difference between hormone-sensitive and castration-resistant to patients.
Advertisement
Advertisement
Editorial Advisory Board
Brian Rini, MD, FASCOEditor | Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center
Thomas Powles, MBBS, MRCP, MDEditor | Director, Barts Cancer Centre at St. Bartholomew's Hospital
Katy Beckermann, MD, PhDEditor | Medical Director of GU Clinical Research at Tennessee Oncology
Christopher Wallis, MD, PhD, FRCSCAssistant Professor of Urology | University of Toronto
Akhil Abraham Saji, MDEditor | Urologist at Swedish Health Services
David Ambinder, MDEditor | Urology Resident at New York Medical College/Westchester Medical Center
The Uromigos Live and Unplugged 2024
The Uromigos Live & Unplugged 2024 took place September 27-29 in Nashville, Tennessee.
This meeting was the third annual in-person event hosted by Thomas Powles, MD, and Brian Rini, MD, FASCO, in partnership with Mashup Media, featuring expert panels and audience discussion around the latest data in genitourinary oncology and vision for the future.
GU Oncology Now delivers the latest news in clinical trials, conference coverage, and more, highlighting advancements in genitourinary oncology treatments and tech.
Get research and breaking news straight to your inbox.
Expert Interviews
Dr. Evan Kovac speaks about his pioneering work with extended reality display technology in urologic surgery and education.
Dr. Zlotta discusses the current state and future of bladder-sparing therapy in MIBC, including how to best select patients.
Dr. Brugarolas reflects on his lab's role in developing HIF-2 inhibitors and his ongoing work to improve patient outcomes.
Dr. Plimack details RETAIN, from early findings with neoadjuvant ddMVAC to the evolution of RETAIN-1 and RETAIN-2.
Drs. Saji and Lebastchi explore focal therapy, covering its historical evolution, techniques, and energy modalities.
Dr. Ghazi is recognized as a pioneer in patient-specific surgical simulation, using state-of-the-art techniques in surgery.
Knowledge Hubs
Curated clinical content based on conditions, therapies, and technologies
The Uromigos
Podcasts hosted by Professors Thomas Powles, MD, and Brian Rini, MD
Conference Coverage
Live meeting highlights
Dr. Chahoud talks about the results of the expansion cohort of the phase 1b STELLAR-002 study.
Dr. Ozay discusses her study that compared the efficacy of cabazitaxel with lutetium Lu-177 in patients with mCRPC.
Dr. Haas provides an update on a 5-year follow-up of KEYNOTE-564 and the survival benefits of adjuvant pembrolizumab for RCC.
BCG plus mitomycin may be an alternative treatment for patients with high-risk NMBIC as access to BCG is limited worldwide.
Video Insights
Clinical discussions with experts in the field
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.